Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATO/ATRA plus idarubicin versus AIDA for newly diagnosed high-risk acute promyelocytic leukemia
NL-OMON47163Phase 3Completed
- Sponsor
- Technische Universität Dresden
- Start
- Apr 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of arsenic trioxide, tretinoin and idarubicin in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Technische Universität Dresden. Primary endpoint: Event-free survival. Started Apr 2018; status: completed.
02
Drugs
arsenic trioxidetretinoinidarubicin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on NL-OMON47163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47163.